ArriVent BioPharma (AVBP) executive compensation, 2026 proxy

Zhengbin (Bing) Yao, Ph.D, Chief Executive Officer and President, was paid $9.4M in 2025, up 290% from $2.4M the year before.

Filed
April 28, 2026
Annual meeting
June 18, 2026
Pay year
2025
Named executives
3
CEO total pay
$9.4M+290% vs prior year
CEO Target Bonus
50%Percentage of base salary
CEO Total Compensation
$9,374,153Fiscal year 2025

How Ph.D was paid

$9.4M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary6%Option awards90%Non-equity incentive4%All other compensation0%

Named executive officers

ExecutiveTotal
Zhengbin (Bing) Yao, Ph.DChief Executive Officer and President$9,374,153
Stuart Lutzker, M.D., Ph.DPresident, Research and Development$3,431,717
Winston Kung, MBAChief Financial Officer and Treasurer$3,407,068

What changed and why

  • $9.4MCEO total compensation increased to $9,374,153 due to higher option award values.
  • $597KBase salary for the CEO increased to $596,667.
  • $358KNon-equity incentive compensation for the CEO rose to $358,000.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.